Reframe-O1/Engot-Ov79/Gog-3086: A Phase II/III Open-Label Study Evaluating The Efficacy And Safety Of Luveltamab Tazevibulin Versus Investigator'S Choice Of Chemotherapy In Women With Relapsed Platinum-Resistant Epithelial Ovarian Cancer Expressing Folate Receptor Alpha (Folr)
Luveltamab Tazevibulin
Below is an instruction that describes a task, paired with an input that provides further context. Write a response that appropriately completes the request. ### Instruction: Identify all the mentioned drugs in the given text. Text may or may not contain drug. If they contain more than 1 drug, use ";" as delimiter and join them. ### Input: Reframe-O1/Engot-Ov79/Gog-3086: A Phase II/III Open-Label Study Evaluating The Efficacy And Safety Of Luveltamab Tazevibulin Versus Investigator'S Choice Of Chemotherapy In Women With Relapsed Platinum-Resistant Epithelial Ovarian Cancer Expressing Folate Receptor Alpha (Folr) ### Output: Luveltamab Tazevibulin